TABLE 3.
Time to alleviation of symptoms (intent-to-treat infected population)
| Population | Parameter | Value |
||
|---|---|---|---|---|
| Peramivir |
Placebo | |||
| 300 mg | 600 mg | |||
| Overall | n | 99 | 97 | 100 |
| Median (h) (95% CI) | 59.1 (50.9-72.4) | 59.9 (54.4-68.1) | 81.8 (68.0-101.5) | |
| Hazard ratioa (95% CI) | 0.681 (0.511-0.909) | 0.666 (0.499-0.890) | ||
| Adjusted P valueb | 0.0092 | 0.0092 | ||
| Influenza virus subtype | ||||
| A/H1 | n | 74 | 69 | 72 |
| Median (h) | 52.5 | 62.6 | 81.4 | |
| Hazard ratio | 0.779 | 0.899 | ||
| Adjusted P value | 0.1458 | 0.5384 | ||
| A/H3 | n | 21 | 25 | 24 |
| Median (h) | 76.1 | 50.5 | 81.0 | |
| Hazard ratio | 0.542 | 0.326 | ||
| Adjusted P value | 0.0556 | 0.0008 | ||
| Symptom duration before study | ||||
| 0-24 h | n | 59 | 51 | 48 |
| Median (h) | 57.2 | 56.1 | 86.7 | |
| Hazard ratio | 0.653 | 0.663 | ||
| Adjusted P value | 0.0516 | 0.0516 | ||
| 24-48 h | n | 40 | 46 | 52 |
| Median (h) | 69.1 | 64.7 | 70.8 | |
| Hazard ratio | 0.708 | 0.694 | ||
| Adjusted P value | 0.1118 | 0.1118 | ||
a
Hazard ratios compared to the placebo group were estimated using Cox proportional-hazards modeling, adjusted for current smoking behavior and composite symptom scores at baseline.
b
P values for comparisons between peramivir and placebo were adjusted using the Hochberg method for multiple comparisons.